Trial | NCT00563108  Report issue

Title

Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
A Double-blind Randomized Single-center Trial of Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation.

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    basiliximab ...

  • Study Participants

    60
Graft-versus-host disease (GVHD) contributes substantially to transplant-related morbidity and mortality. Steroids remains first line therapy for acute GVHD but there is currently no consensus on second line therapy for those in whom steroids have been ineffective. Basiliximab has been shown to be a safe and effective immunosuppresant in the prevention and treatment of rejection after renal transplantation and its role in acute GVHD prophylaxis and treatment has been described favourably. This is a randomized control trial to investigate its efficacy and safety in the management of acute GVHD post allogeneic stem cell transplantation (SCT).
Study Started
Jun 30
2004
Study Completion
Dec 31
2008
Anticipated
Last Update
Jul 07
2010
Estimate

Drug Basiliximab

Drug Placebo

Criteria 

Inclusion Criteria:

Grade II to IV acute GVHD after SCT

Exclusion Criteria:

Known allergy to basilixmab
No Results Posted